Biora: FDA OKs IND Application for Drug/Device Combo for Ulcerative Colitis

 BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis.

https://www.globenewswire.com/news-release/2023/11/30/2788995/0/en/Biora-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-Drug-Device-Combination-BT-600-Targeting-Treatment-of-Ulcerative-Colitis.html